Vanguard Group
CDTX

Vanguard Group’s Cidara Therapeutics CDTX Stock Holding History

Vanguard Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$443M Buy
2,007,193
+776,527
+63% +$126M 0.01% 1128
2025
Q3 		$118M Buy
1,230,666
+263,961
+27% +$16.8M ﹤0.01% 1785
2025
Q2 		$47.1M Buy
966,705
+457,129
+90% +$11M ﹤0.01% 2146
2025
Q1 		$11M Buy
509,576
+292,072
+134% +$6.49M ﹤0.01% 2795
2024
Q4 		$5.85M Buy
217,504
+36,969
+20% +$601K ﹤0.01% 3211
2024
Q3 		$1.94M Hold
180,535
– – ﹤0.01% 3566
2024
Q2 		$2.16M Buy
180,535
+13,222
+8% +$181K ﹤0.01% 3531
2024
Q1 		$3.08M Hold
167,313
– – ﹤0.01% 3456
2023
Q4 		$2.66M Buy
167,313
+2,715
+2% +$43.6K ﹤0.01% 3500
2023
Q3 		$3.1M Buy
164,598
+4,267
+3% +$83.8K ﹤0.01% 3440
2023
Q2 		$3.62M Hold
160,331
– – ﹤0.01% 3452
2023
Q1 		$4.07M Buy
160,331
+36,873
+30% +$1.05M ﹤0.01% 3401
2022
Q4 		$1.87M Buy
123,458
+61
+0% +$728 ﹤0.01% 3682
2022
Q3 		$1.55M Buy
123,397
+315
+0.3% +$4.35K ﹤0.01% 3852
2022
Q2 		$1.2M Hold
123,082
– – ﹤0.01% 4017
2022
Q1 		$2.05M Sell
123,082
-767
-0.6% -$13K ﹤0.01% 3950
2021
Q4 		$3.15M Buy
123,849
+24,331
+24% +$757K ﹤0.01% 3856
2021
Q3 		$4.46M Buy
99,518
+196
+0.2% +$7.45K ﹤0.01% 3729
2021
Q2 		$4.01M Sell
99,322
-7,734
-7% -$327K ﹤0.01% 3701
2021
Q1 		$5.7M Buy
107,056
+12,048
+13% +$595K ﹤0.01% 3462
2020
Q4 		$3.8M Sell
95,008
-36,362
-28% -$1.81M ﹤0.01% 3479
2020
Q3 		$7.49M Buy
131,370
+47,473
+57% +$3.35M ﹤0.01% 2938
2020
Q2 		$6.19M Buy
83,897
+20,733
+33% +$1.34M ﹤0.01% 3002
2020
Q1 		$3.13M Buy
63,164
+29,210
+86% +$1.75M ﹤0.01% 3165
2019
Q4 		$2.61M Hold
33,954
– – ﹤0.01% 3373
2019
Q3 		$1.35M Sell
33,954
-1,928
-5% -$64.8K ﹤0.01% 3566
2019
Q2 		$1.21M Sell
35,882
-12,435
-26% -$517K ﹤0.01% 3617
2019
Q1 		$2.56M Buy
48,317
+5,030
+12% +$276K ﹤0.01% 3370
2018
Q4 		$2.03M Buy
43,287
+10,263
+31% +$732K ﹤0.01% 3371
2018
Q3 		$2.91M Buy
33,024
+4,299
+15% +$379K ﹤0.01% 3411
2018
Q2 		$2.99M Buy
28,725
+470
+2% +$44.4K ﹤0.01% 3379
2018
Q1 		$2.26M Sell
28,255
-28
-0.1% -$3.83K ﹤0.01% 3419
2017
Q4 		$3.85M Buy
28,283
+644
+2% +$97.7K ﹤0.01% 3232
2017
Q3 		$4.48M Buy
27,639
+12,612
+84% +$1.79M ﹤0.01% 3161
2017
Q2 		$2.25M Sell
15,027
-2,132
-12% -$295K ﹤0.01% 3345
2017
Q1 		$2.68M Buy
17,159
+535
+3% +$94K ﹤0.01% 3286
2016
Q4 		$3.46M Buy
16,624
+7,345
+79% +$1.53M ﹤0.01% 3184
2016
Q3 		$2.13M Buy
9,279
+667
+8% +$154K ﹤0.01% 3370
2016
Q2 		$1.78M Buy
8,612
+499
+6% +$121K ﹤0.01% 3410
2016
Q1 		$2.06M Buy
8,113
+1,386
+21% +$319K ﹤0.01% 3370
2015
Q4 		$2.31M Buy
6,727
+1,718
+34% +$516K ﹤0.01% 3337
2015
Q3 		$1.27M Buy
5,009
+697
+16% +$199K ﹤0.01% 3550
2015
Q2 		$1.21M Buy
+4,312
New +$1.33M ﹤0.01% 3605

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Group's CDTX Position: Q4 2025 in Review

Vanguard Group increased its Cidara Therapeutics (CDTX) stake by 63% in Q4 2025, buying an estimated $126M and bringing the position to 2,007,193 shares worth $443M. The position accounts for 0.01% of the portfolio, ranked #1128.

Vanguard Group first reported a position in CDTX in Q2 2015 and has held it in 43 quarters since. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Vanguard Group held 2,007,193 shares of Cidara Therapeutics worth $443M as of Q4 2025.
  • Vanguard Group bought 776,527 Cidara Therapeutics shares in Q4 2025, an estimated $126M.
  • Cidara Therapeutics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1128 holding.
  • Vanguard Group first reported a position in Cidara Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.